Aspacytarabine

Small moleculeexperimental

Chemistry & pharmacology

Loading structure…

SMILES

N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Mol. weight
358.31 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05503355Phase 1/Phase 2 (Phase 2)Aug 17, 2022BioSight Ltd.
NCT04749355Phase 2Aug 14, 2021BioSight Ltd.
NCT04827719Phase 2May 1, 2021Groupe Francophone des Myelodysplasies, Institut Paoli-Calmettes, University of Paris
NCT03435848Phase 2Aug 14, 2018BioSight Ltd.
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BioSight Ltd.For profit3312018
Groupe Francophone des MyelodysplasiesAcademic/Hospital1112021
Institut Paoli-CalmettesAcademic/Hospital1012021
University of ParisAcademic/Hospital1012021
4 organizations
Page 1 / 1